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ABSTRACT: Endocrinology is one of several medical specialities 
that have been gradually transformed by a deeper understanding of 
the molecular bases of disorders. Genetic testing with the purposes 
of defining a precise molecular diagnosis has increasingly gained 
space in the routine assessment of patients with endocrinopathies, 
and the advent of massive parallel sequencing (MPS) is boosting 
the incorporation of molecular information in the clinic. The 
main benefit of genetic testing is diagnostic precision, resulting 
in improved and individualized care for patients and family 
members, and better disease prevention. However, genetic tests 
are not infallible and may bear several potential risks, being thus 
indicated when clinical suspicion is strong and the benefit of 
determining a molecular diagnosis is unambiguous. In this review, 
these evolving concepts and current indications for molecular 
diagnosis in endocrinology will be explored. Molecular tools will 
be revised and contextualised, including those aimed at identifying 
changes in gene dosage (karyotpe, FISH, MLPA, aCGH, 
SNParray) or in the DNA nucleotide sequence (allele-specific 
PCR, RFLP, Sanger sequencing, MPS or NGS). Finally, matters 
surrounding the complex attribution of biologically relevant 
functional impact to identified DNA variants will be explored, 
together with the challenges brought by high throughput molecular 
analysis. These are exciting times for molecular endocrinology, 
and hopefully soon a translation to multiple benefits for patients 
will be self-evident.
Keywords: Genetic testing; Endocrinology; Mutation; DNA 
mutation analysis; Transcription, genetic; Genetic markers; 
Sequence analysis, DNA/methdos; Molecular sequence data.
RESUMO: A endocrinologia é uma de muitas especialidades 
médicas que vem sendo transformada pelo maior conhecimento 
das bases moleculares das doenças. O teste genético com o 
propósito de definir o diagnóstico molecular vem ganhando espaço 
na avaliação rotineira de pacientes com endocrinopatias, e o 
advento do sequenciamento paralelelo em larga escala (SPLE) está 
ampliando o potencial de incorporação da informação molecular 
na prática clínica. O principal benefício do teste genético é a 
precisão diagnóstica, resultando em melhora e individualização 
do tratamento de pacientes e seus familiares, e da prevenção de 
doenças. Entretanto, testes genéticos não são infalíveis e podem 
trazer alguns riscos potenciais, estando portanto indicados quando 
a suspeita clínica é forte e o benefício do diagnóstico molecular 
é claro. Nesta revisão serão explorados conceitos genéticos 
em evolução e as atuais indicações de diagnóstico molecular 
em endocrinologia. Ferramentas moleculares serão revisadas, 
incluindo aquelas visando a identificação de alterações no número 
de cópias gênicas (cariótipo, FISH, MLPA, aCGH, SNParray) ou 
na sequencia nucleotídica do DNA (PCR alelo-específica, RFLP, 
sequenciamento Sanger, SPLE ou NGS). Ainda, serão discutidos 
os percalços da difícil atribuição de impacto funcional e relevância 
biológica a variantes de DNA identificadas, e os desafios atuais das 
tecnologias de análise molecular de larga escala. A endocrinologia 
molecular vive um momento transformador e empolgante, com 
o potencial de, em breve, se traduzir em múltiplos benefícios no 
cuidado de nossos pacientes.
Descritores: Testes genéticos; Endocrinologia; Mutação; 
Análise mutacional de DNA; Transcrição genética; Marcadores 
genéticos;Análise de sequência de DNA/métodos; Dados de 
sequência molecular.
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INTRODUCTION
The genetic bases of endocrinopathies have been progressively unravelled over the past decades, 
resulting in an increasing availability and clinical relevance 
of molecular diagnostics. Initially, a defined molecular 
pathogenesis was established for rarer endocrine conditions 
such as developmental defects and hereditary disorders, but 
more recently the genetic contribution to common endocrine 
diseases, such as obesity and osteoporosis, have begun to be 
understood1-4. The advent of automated Sanger sequencing 
in the 1990s and the recent emergence of massive parallel 
sequencing have driven these advances5,6. Indeed, while 
it may be still early days to consider including molecular 
tests in the routine assessment of every patient presenting 
with an endocrine complaint, the future endocrinologist will 
certainly need to be able to aptly construe the significance 
of molecular diagnostic reports.
In certain scenarios, which will be detailed 
throughout this review, a precise molecular diagnosis has 
a clear benefit and allows for better care, impacting on 
therapeutic decisions, on the prevention of complications 
and on accurate genetic counselling of affected individuals 
and family members. Nevertheless, genetic testing is not 
infallible and has technical limitations, and therefore 
should only be pursued when the clinical suspicion of a 
molecular defect is high and the benefit of the test is clear. 
More importantly, it is becoming apparent that most allelic 
variants found on individual genomes are devoid of an 
immediately clear functional effect, and thus the finding of 
sequence variants on candidate genes for endocrine diseases 
should always be followed by an exhaustive appraisal of 
its potential biological relevance7,8.
In this review, the current applicability of genetic 
testing in endocrinology and the most common molecular 
tools used for this intent will be discussed. Of note, ‘genetic 
testing’ will be used throughout this text as an umbrella 
definition for any procedure aiming at establishing a 
molecular diagnosis.
CLINICAL SUSPICION OF A MOLECULAR 
DEFECT
Several clinical, laboratory and image findings 
might point towards a genetic cause for an endocrinopathy. 
For example, hyperparathyroidism is a fairly common 
disorder in postmenopausal women, but if manifesting 
in a young individual (< 30 years-old) it should arise the 
suspicion for type 1 multiple endocrine neoplasia (MEN1) 
due to MEN1 mutations, prompting investigation for 
pituitary and enteropancreatic tumours and additional 
familial cases9,10. Conversely, if imaging reveals jaw 
tumours in such patient, a differential diagnosis with 
hyperparathyroidism jaw tumour syndrome caused by 
CDC73 (HRPT2, parafibromin) mutations is important, 
due to the increased risk of parathyroid carcinoma11. Thus, 
the combination of history, symptoms and signals, and 
traditional diagnostic workup will point to the suspicion 
of a genetic cause in most cases. 
Besides such disease-specific indicators, actively 
inquiring and obtaining a fully detailed family history is 
essential, even if similar familial cases are not spontaneously 
brought up by the patient. Indeed, many genetic disorders 
may present with variable expressivity within families, 
justifying the investigation of associated features even 
if the main phenotypic characteristic is absent in family 
members12. Returning to the MEN1 example given above, 
a patient presenting with hyperparathyroidism may fail to 
recollect precisely similar cases in the family, but might 
mention relatives with a history of recurrent peptic ulcer or 
milk discharge, which could be manifestations of MEN1-
associated tumours.
While obtaining the family history, it is also 
important to explore the possibility of consanguinity, 
which could favour the occurrence of autosomal recessive 
disorders. Finally, when obtaining a sample for genetic 
testing from an individual, it is wise to try to obtain samples 
from 1st degree relatives as well, especially if obtaining such 
samples in the future would be logistically challenging – the 
availability of related samples is paramount for analysing 
phenotypic segregation of identified genetic variants. As it 
will be discussed later, evidence of co-segregation helps to 
ascertain the biological impact of genetic variants8.
INDICATIONS FOR GENETIC TESTING
Any diagnostic procedure based on an individual’s 
DNA, RNA, chromosomal or protein samples aiming 
to detect genotypes associated to genetic or hereditary 
disorders can be considered a genetic test. As detailed in 
major guidelines, genetic testing has several benefits but 
may also have risks13,14. 
The main benefit of a genetic test is allowing for 
a specific and precise molecular diagnosis. Important 
additional benefits stem from this diagnostic precision, such 
as improved and individualized follow-up, the possibility 
of offering a specific treatment, with better prediction 
of response, and prevention of complications. Further 
benefits of a molecular diagnosis include the anticipation 
of hereditary transmission and the appropriate vigilance 
and care of identifiable family members. A few examples 
of endocrine scenarios where a genetic test is beneficial 
include:
•	Identifying a RET mutation in a patient with 
medullary thyroid carcinoma allows early recognition of 
potentially affected family members and better disease 
control15;
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•	Identifying a MEN1 mutation in a patient with 
hyperparathyroidism enables vigilance for pituitary and 
enteropancreatic tumours, and screening of relatives9;
•	Identifying HNF1A or HNF4A defects in a patient 
with diabetes could shift their treatment to sulfonylureas, 
with better response and compliance in comparison to daily 
insulin administration16;
•	Identifying a PROP1 mutation in a child with short 
stature will prompt vigilance of adrenal insufficiency, a late 
but potentially lethal manifestation17.
On the other hand, genetic tests may bear several 
potential risks. Amongst these, the most serious ones are 
related to the potential breach of ethical, moral and legal 
principles. In order to avoid such risks, it is essential to offer 
appropriate pre- and post-test genetic counselling, making 
sure that the patient understands the nature of genetic 
testing, its advantages and limitations, and exploring 
the potential consequences of a molecular diagnosis in 
the personal and familial realms, taking into account the 
individual’s social and cultural contexts. It is also important 
to obtain informed consent, signed by the patient or 
their legal representative and by the attending physician, 
recording all aspects discussed during counselling. These 
precautions are particularly important when a molecular 
diagnosis carries a heavy burden in terms of prognosis: 
for example, identifying a germline TP53 mutation in an 
adolescent means that tumour vigilance will be necessary 
throughout life, and, for some, such perspective might result 
in overwhelming anxiety18. Finally, as with all aspects of 
doctor-patient relationship, protecting the confidentiality 
of the individual’s genetic identity is paramount.
Other potential risks of genetic testing derive from 
the nature of the laboratory test employed: technical 
limitations, errors in its interpretation (e.g., a negative result 
in a mutational analysis directed at hot spots in a candidate 
gene does not exclude the possibility of damaging variants 
in other parts of the gene), and lack of technical quality. 
Hence, taking into account benefits and risks, genetic 
tests are currently indicated when clinical suspicion is 
strong and the benefit of determining a molecular diagnosis 
is unambiguous. While compiling a comprehensive list 
of all indications for genetic testing in endocrinology is 
unfeasible due to the fast-paced evolution of knowledge 
in the field, a selection of endocrinopathies for which a 
molecular diagnosis is currently considered to be beneficial 
is shown on Table 1. Several more indications may exist, 
being increasingly recognised in light of their potential 
benefits in personalising care, and therefore indicating a 
genetic test must be an individualised decision.
Table 1. Selected endocrinopathies for which genetic testing is indicated due to clear benefits of a molecular diagnosis
Disease (OMIM identifier) Gene When to suspect and test
Familial medullary thyroid carcinoma 
(#155240) RET All patients with medullary thyroid carcinoma
Multiple endocrine neoplasia type 2 
(MEN2, #171400 and #162300) RET
Association of MEN2-related tumours (medullary 
thyroid carcinoma, pheochromocytoma and others), 
see Wells et al.15
Multiple endocrine neoplasia type 1 
(MEN1, #131100) MEN1
Association of two or more MEN1-related tumours 
(parathyroid, enteropancreatic, pituitary), see Thakker 
et al.9
Pheochromocytoma and paragangliomas 
(#171300)
VHL, RET, TMEM127, 
MAX, SDHB, SDHD, etc
Early-onset, familial, bilateral or malignant 
pheochromocytomas; early-onset paragangliomas
Li-Fraumeni syndrome (#151623) TP53
Early onset of multiple tumours, such as soft tissue 
sarcomas and osteosarcomas, breast cancer and 
adrenocortical carcinoma, with autosomal dominant 
inheritance
Glucocorticoid-remediable aldosteronism 
(#103900)
CYP11B1 /CYP11B2 
chimeric gene
Early-onset hyperaldosteronism, autosomal dominant 
inheritance
Congenital adrenal hyperplasia due to 
21-hydroxylase deficiency (#201910)
CYP21A2
When parents of an index case (classic form) 
plan a new gestation and would consider prenatal 
dexamethasone treatment
OMIM, online Mendelian inheritance in men database (http://www.ncbi.nlm.nih.gov/omim). Adapted from Ferraz-de-Souza et al.47
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TOOLS AND METHODS COMMONLY USED FOR 
ESTABLISHING A MOLECULAR DIAGNOSIS
Obtaining samples and choosing the appropriate tool for 
molecular diagnosis
Most frequently, a molecular diagnosis is made 
upon samples of genomic DNA, i.e. nuclear chromosomal 
DNA present in all cells and passed from one generation 
to the next. In certain situations, however, samples of 
tissue- or cell-specific DNA and/or RNA are analysed to 
identify somatic variants and patterns of gene expression 
(transcriptome). It is also possible to perform a molecular 
investigation by obtaining samples of live cells (e.g. 
skin fibroblasts), allowing the characterisation of protein 
expression and function, for example. While transcriptomics 
and proteomics are surging in certain areas of endocrinology 
such as in cancer care as a means to understand and predict 
disease behaviour, RNA- and protein-based diagnosis are 
beyond the scope of this review, which will focus hereafter 
on DNA-based techniques.
Pathogenic variants in genomic DNA are termed 
germline mutations, and therefore can be transmitted to 
offspring; these correspond to the main types of mutations 
discussed throughout this text. In contrast, somatic DNA 
variants are those restricted to specific cells and their 
progeny in their course of division and differentiation, other 
than germ cells. Thus, somatic variants cannot be passed 
on to offspring. Endocrine examples of non-inheritable 
genetic disorders due to somatic mutations are fibrous 
dysplasia of bone and McCune Albright syndrome caused 
by GNAS defects19.
Samples of genomic DNA can be easily obtained 
from peripheral blood leukocytes following a routine blood 
draw, generally yielding good amounts of high quality 
DNA after extraction. It is also possible to obtain good 
quality DNA from saliva samples, which can be particularly 
interesting for field work (analysis of large families or 
population, for example) and for obtaining DNA samples 
from children.
Once the sample is secured, it is important to choose 
molecular diagnostic procedures that are most appropriate 
for the suspected defect. This important step cannot be 
overlooked, because if the wrong molecular tool is chosen, 
a “normal” result will not exclude that a molecular defect, 
which was not appropriately investigated, is in fact causing 
the disease. Broadly, DNA defects can be simplified into 
two categories (at the expense of ill defining particular 
situations, of course): changes in the number of gene 
copies (gene dosage) or changes in the DNA nucleotide 
sequence. Changes in gene dosage include abnormalities 
in chromosomal numbers, chromosomal translocations, 
deletions or duplications, large insertions and deletions 
(indels) and gene copy number variants. In these situations, 
the nucleotide sequence is generally unchanged (except 
where the breaking points for structural changes are 
located), but gene copies are in excess (duplication) or 
lacking (deletion) in the genome, resulting in altered gene 
dosage20. Changes in the DNA nucleotide sequence, on the 
other hand, range from single nucleotide variants (SNVs) 
to small insertions and deletions, and may affect the coding 
frame resulting in defective proteins. As will be shown 
below, tools for investigating these two categories of DNA 
variation are largely different, and it is up to the clinician 
to individually choose which direction to follow, based 
on the knowledge of the genetic defects most commonly 
associated with each endocrinopathy.
 
Searching for chromosomal abnormalities, large indels 
and copy number variants
A first step to analysing large structural abnormalities 
in chromosomes is the karyotype, a genetic tool that 
has been around for decades and still is very useful, 
particularly in the approach to children with disorders of 
sex development, short stature and pubertal abnormalities. 
A karyotype is usually obtained from culturing peripheral 
blood leukocytes, and analysing the number and appearance 
of chromosomes under light microscopy. Examples of 
situations in which a karyotype can guide the diagnostic 
approach or establish the diagnosis itself include the 
investigation of ambiguous genitalia in the neonate, of 
girls with short stature due to Turner syndrome (45,X 
and variants) and of pubertal abnormalities in boys due to 
Klinefelter syndrome (47,XXY)21.
Refining cytogenetics in the 1980s led to the 
development of Fluorescent In Situ Hybridization, or FISH, 
based on the use of fluorescent probes that bind to specific 
chromosomal regions, allowing the detection of finer 
chromosomal deletions, insertions or translocations. Unlike 
a normal karyotype, FISH requires a pre-test knowledge of 
which chromosomal regions to analyze. In the context of 
endocrine disorders, FISH can be used in the investigation 
of 46,XX disorders of sex development to ascertain the 
presence of a translocated SRY, and to diagnose Prader-
Willi syndrome (15q11-13 critical region).
In recent decades, major interest has been placed 
onto unravelling submicroscopic structural abnormalities. 
Copy number variants (CNVs) can result from deletions 
or duplications involving exons, whole genes or a group of 
genes, and can be investigated in an individual gene basis 
or in genomic scale.
Individual gene CNVs are best analysed using 
Multiplex Ligation-dependent Probe Amplification 
(MLPA), given its practicality and accuracy. MLPA 
employs fluorescent-labelled oligonucleotides that bind 
specific DNA regions and require physical proximity in 
order to be amplified, allowing the comparison of signal 
intensity for regions of interest versus neighbouring 
regions. Applications for MLPA in endocrinology include 
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the search for gene deletions in monogenic diabetes (e.g. 
GCK deletions in MODY2) and in short stature (e.g. 
SHOX deletion)22. More recently, the advent of microarray 
technologies has allowed the investigation of CNVs in 
genomic scale using techniques such as array Comparative 
Genomic Hybridization (aCGH) or Single Nucleotide 
Polymorphism (SNP) arrays. In aCGH, a whole proband 
genome is individually compared to a reference genome, 
allowing detection of gains or losses, and through the 
detailed genotyping generated by SNP arrays, duplicated 
or deleted regions also become apparent. These exciting 
techniques are somewhat limited to the research realm, but 
have been increasingly used for the diagnosis of complex 
syndromic phenotypes23.
Bearing in mind that most genes located in 
autosomes are expressed in double dosage, from copies 
on both maternal and paternal alleles (with the notable 
exception of those under genomic imprinting), complete 
or partial deletion of genes can result in biologically 
relevant changes in the dosage of codified proteins. When 
a deletion affects only one of the copies, for example, 
resulting haploinsufficiency might have a functional 
manifestation. Therefore, when looking for sequence 
variants in a candidate gene for an autosomal dominant 
disorder, if sequencing results return absolutely normal, 
one might consider the possibility of a heterozygous 
deletion, which would go undetected on DNA sequencing. 
In these cases, using MLPA would allow the identification 
of haploinsufficiency as a potential cause for the observed 
phenotype. Situations like these alert the clinician to the 
realisation that “normal” results in specific genetic tests not 
always mean that a molecular defect is absent.
Searching for single nucleotide variants and small indels
Changes in the DNA nucleotide sequence, such as 
single nucleotide (point) substitutions or small insertions 
or deletions, have long been sought as the cause of genetic 
disorders. Indeed, an error in the DNA coding frame 
may reasonably lead to a dysfunctional protein with 
physiological consequences. Even though DNA sequencing 
using chain terminators had been devised by Frederick 
Sanger in 1977, it was the development of polymerase chain 
reaction (PCR) as a means to easily amplify DNA by Mullis 
and others, in 1988, that really propelled molecular genetics 
into a new era24. In general, for traditional mutational 
analysis, several rounds of DNA amplification are necessary 
in order to obtain sufficient amounts of the target region. 
Hence, PCRs became a staple of every molecular biology 
lab from the 1990s onwards.
Polymerase chain reactions are easily performed 
on a thermocycler, using a thermostable DNA polymerase 
(most frequently Taq, from the bacteria Thermus aquaticus) 
and oligonucleotides (commonly referred to as primers) 
that recognise and hybridise specific DNA sequences at 
the borders of the target region. Therefore, an important 
characteristic (and perhaps limitation) of PCR is that the 
target area, or at least its boundaries, has to been previously 
known. Oligonucleotides are specifically designed for each 
piece of DNA to be amplified, manually or using freely 
available online software platforms (e.g. Primer3Plus), 
based on a reference sequence for the human genome.
Of note, several online resources have become 
available that provide guidance navigating the increasing 
wealth of genetic and molecular knowledge, and some 
are worth mentioning. Genome browsers provide up-to-
date validated information on a candidate gene’s location, 
structure and sequence (for example, Ensembl, UCSC 
genome browser, NCBI’s Entrez Gene) and therefore 
can provide a reference guiding oligonucleotide design. 
Official gene symbols are curated by the Human Genome 
Nomenclature Committee (HGNC) and can be checked at 
www.genenames.org to make sure the correct candidate 
gene is being selected, since gene symbols frequently 
overlap. Finally, the Human Genome Variation Society 
(HGVS) issues guidelines on how to accurately and 
uniformly describe sequence variants (found at www.hgvs.
org/mutnomen/), informing the report of identified variants.
PCR-based techniques
Straightforward PCR-based techniques such 
as allele-specific PCR and restriction fragment length 
polymorphism (RFLP) analysis can provide quick and 
accurate molecular diagnosis when searching for a specific 
pre-known nucleotide variant. Thus, these techniques are 
particularly useful for confirming variants identified by 
sequencing, for genotyping control populations in order to 
infer allelic frequencies, and for screening affected family 
members following the identification of an index case.
Allele-specific PCR adds a twist to standard PCR: 
normally, oligonucleotides target an invariant part of the 
genome to secure the amplification of a in-between region 
where the variant might be; in allele-specific PCR, however, 
one of the oligonucleotides is directed at the variant itself. 
This way, detection of an amplification product on agarose 
gel electrophoresis indicates that the variant of interest is 
indeed present. Since the whole experiment can be done 
cheaply in a few hours, allele-specific PCR is particularly 
useful for rapid genotype screening of large populations.
RFLP employs differential DNA digestion by 
restriction endonucleases to discriminate between wild 
type and altered sequences. Restriction enzymes were 
originally discovered in bacteria, where they serve as a 
defence mechanism against viral infections, and have the 
ability to cut the DNA at very specific nucleotide sequences, 
known as recognition sites. A profusion of such enzymes are 
now available, both natural and recombinant, and therefore 
several nucleotide sequences can be targeted. Thus, in 
order for this technique to be applicable, it is necessary 
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that the DNA variant of interest introduces or abolishes an 
endonuclease recognition site – several online tools analyse 
input nucleotide sequences and display existing restriction 
sites (for example, NEBcutter) in order to aid experimental 
design. RFLP has been extensively used to confirm variants 
identified by sequencing and to screen family members.
Sanger sequencing
Detecting terminally labelled amplification products 
through capillary electrophoresis constitutes the basis of 
Sanger sequencing, the most widely used technique to 
sequence DNA for the purposes of molecular diagnosis 
(so far). Automated sequencing protocols involve a 
second PCR, termed the “sequencing reaction”, using 
labelled chain-terminating dideoxynucleotides that 
allow the identification of A, T, C or G after capillary 
electrophoresis. The result is graphically displayed as an 
electropherogram, which can be visually analysed in order 
to compare the sequence of interest to the reference (wild 
type). Given the nature of chain-terminating nucleotides 
used for sequencing, only one primer is used in the reaction, 
determining the reading direction, sense or antisense. 
Although sequencing can be routinely done only in one 
direction for the purposes of screening, if there are quality 
issues (weak peak intensity, too much background noise) 
or if a variant is found and needs confirmation, the process 
must be repeated using the opposite primer. 
Examples of the application of Sanger sequencing 
for mutational analysis and genotyping in endocrinology 
are bountiful in the literature. Some practical tips may help 
beginners eyeballing several electropherograms: a) updated 
reference DNA sequences (to be used for comparison) can 
be obtained from the genome browsers mentioned above; b) 
considering that genome assemblies and gene annotations 
may vary from time to time, it is critical to take note and 
report the identifier of the reference sequence used; and c) 
be sure to obtain images of critical findings: when reporting 
Sanger sequencing results, electropherograms displaying 
the identified variants are customarily shown25. 
Massive parallel sequencing
For all the usefulness of Sanger sequencing, and 
the vast experience amassed with this methodology, it 
has two notable limitations hampering its application to 
the discovery of new genes in endocrinopathies: analysed 
regions have to be pre-selected, meaning that candidate 
genes have to be previously known or hypothesized, and 
it can become quite laborious if several sequences need to 
be analysed (it bears saying that, on average, good Sanger 
reading is obtained for stretches up to 500 base pairs). From 
2005 onwards, high throughput sequencing technologies 
became available, revolutionising mutational analysis to a 
new era of genomic scale, big data and fast results; these 
technologies are commonly referred to as “next generation 
sequencing” but are perhaps better described as massive 
parallel sequencing (MPS)26.
A few MPS platforms exist, and methodology and 
throughput are variable. All share the ability to sequence 
several different stretches of DNA at the same time, the 
possibility of barcoding, allowing simultaneous analysis 
of more than one individual, and generation of large data27. 
Therefore, while the hands-on experimental part of MPS 
might be relatively simple, the technology (platforms, 
consumables, etc) is still expensive and the bioinformatics 
analysis is still somewhat burdensome – both are fast 
improving, rendering MPS more accessible. Possible 
applications include the analysis of the whole genome 
(whole genome sequencing, or WGS), of all coding exons 
of known genes (whole exome sequencing, WES) and of 
selected gene panels.
This paradigm shift in molecular analysis has been 
fully embraced in the endocrine field, both in research 
and at the clinic28. If the use of WGS in the clinical front 
has been so far limited to the diagnosis of severe complex 
phenotypes29, WES is now easily available as a diagnostic 
test and can be very useful for obtaining a molecular 
diagnosis in endocrinopathies for which several candidate 
genes exist, such as disorders of sex development6,30. 
Indeed, implementing MPS in endocrine research has 
allowed the discovery of new molecular mechanisms in 
rare and common disorders, such as precocious puberty 
and obesity, respectively2,31. Due to cost-effectiveness, 
candidate gene panels are promising to take Sanger 
sequencing’s place as first choice test in the molecular 
diagnosis of genetically heterogeneous endocrine disorders, 
such as monogenic diabetes and osteogenesis imperfecta32.
CONFIRMING AND ASCERTAINING THE 
BIOLOGICAL IMPACT OF DNA VARIANTS
Identifying a sequence variant within a candidate 
gene is always an exciting moment in a molecular biology 
lab. Nevertheless, several rounds of subsequent analysis 
are necessary to confirm the finding and to ascertain its 
biological impact, i.e. to try to establish causality for the 
observed phenotype. This can be a particularly daunting 
task in view of the hundreds of thousands of DNA variants 
we all carry in our genomes, most of which have no 
identifiable repercussion33,34.
Firstly, the sequence variant identified by Sanger 
or MPS must be confirmed. For that, it is good practice to 
repeat the experiment from the beginning, from the initial 
DNA amplification (some go as far as obtaining a new DNA 
sample to discard contamination). If the observed results 
are still the same, they need be confirmed by a different 
methodology - alelle-specific PCR or RFLP can be used 
for this purpose. 
Once confirmed, the potential biological impact of 
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the identified variant must be established. It is wise to start 
by checking if the variant is novel or has been previously 
described in association with the observed phenotype, or 
as a polymorphic variant. Several databases might aid 
this search, from PubMed, GoogleScholar and OMIM to 
Ensembl, dbSNA, HapMap, 1000Genomes, ExAC and 
Exome Variant Server. Frequently, pre-analysed MPS 
reports will already come with this information. For 
variants identified by Sanger sequencing, it is crucial to 
correctly describe variants according to HGVS guidelines 
in order to guarantee that this search is effective. 
Whenever a DNA variant is postulated to be 
associated with a phenotypic trait or disorder, it becomes 
essential to investigate co-segregation within the family 
and its frequency in a control population of similar ethnic 
background. As discussed above, allele-specific PCR 
or RFLP can be a practical means for such familial and 
population screenings.
In general, attributing a functional impact for 
single nucleotide variants (SNVs, or point variants) 
is challenging, but their type and location within the 
structure of the gene may give important clues to potential 
functional effects. Traditionally, SNVs located inside the 
coding region of a gene are termed a) nonsense, if they 
introduce a premature stop codon (TAG, TAA or TGA); 
b) missense or nonsynonymous if they result in amino 
acid change; or c) synonymous, if the coded amino acid is 
unchanged. These concepts have been evolving with the 
advent of MPS, and the term ‘loss-of-function’ (LoF) has 
been increasingly used in the literature to describe variants 
more frequently expected to result in protein impairment, 
including nonsense or splice site-disrupting SNVs, indels 
disrupting the coding frame, or larger deletions35.
Nonsense SNVs are expected to code for 
truncated proteins with reduced (or abolished) function; 
therefore, attributing a biological impact is usually more 
straightforward. For example, we have followed for several 
decades a patient with severe hereditary vitamin D-resistant 
rickets due to a nonsense mutation in the vitamin D receptor 
(VDR)25. While wild type VDR has 427 amino acids, this 
patient’s homozygous mutation introduces a premature 
stop codon at residue 30, meaning that the resulting protein 
function is severely dysfunctional.
On the other hand, nonsynonymous SNVs may have 
different degrees of functional effect. The investigation of 
the potential functional effect of a nonsynonymous SNV 
involves gathering several lines of evidence supporting a 
causative role, such as: a) comparing the physicochemical 
properties of wild type and changed amino acids; b) 
analysing the degree of amino acid conservation amongst 
species (UCSC genome browser and ClustalW2 are useful 
to this purpose); c) locating the change amino acid within 
the protein functional domains (this information can be 
found at Uniprot); d) in silico prediction of functional 
effect (several freely available web-based software tools 
can be used, such as PolyPhen, SIFT, MutationTaster 
and Mutalyzer); d) in silico protein modelling, aiming 
to identify changes in tertiary protein structure; and 
e) in vitro functional studies, which require previous 
knowledge of protein function and are often laborious, 
requiring considerable laboratory set up and expertise 
with the devised experiment, but are generally regarded 
as strong evidence of effect. For example, in the study of 
several different mutations in the pivotal nuclear receptor 
steroidogenic factor-1 (SF-1, NR5A1), many of these lines 
of evidence were gathered to establish a functional impact 
on adrenal, gonadal and reproductive phenotypes36.
Finally, despite the lack of a direct effect on the 
protein amino acid sequence, synonymous SNVs or those 
located in untranslated, intronic or promoter regions may 
still have important biological repercussions, particularly if 
affecting gene expression or mRNA splicing. For example, 
somatic mutations in the promoter region of TERT may lead 
to thyroid cancer, with potential diagnostic implications37, 
and homozygous splice site mutations in the GH-releasing 
hormone receptor (GHRHR) can lead to short stature due 
to growth hormone deficiency38.
H I G H  T H R O U G H P U T T E C H N O L O G I E S : 
CHALLENGES OF A NEW ERA
Right now, in endocrinology and throughout 
health sciences, we are fast paced towards Genomic 
or Personalised Medicine39. Ever-improving MPS 
technologies are expected to bring down costs, and better 
navigation and understanding of accumulated genomic 
data will translate into biologically relevant information, 
so that in the not-so-far future individuals may choose 
to fully sequence their full genomes with the hopes of 
more accurately predicting and preventing diseases40,41. It 
will certainly be challenging for clinicians to incorporate 
this information into their assessment and management 
of individual patients, but the potential for precision is 
seemingly undeniable.
As a result of widespread availability of MPS, 
several challenges are currently being met in research and 
clinical settings. For example, ascertaining the impact 
of the hundreds of thousands of DNA variants identified 
in individual genomes is not easy; the term ‘variants of 
uncertain (or unknown) significance’ (VUS) has arisen 
to collectively describe variants without an immediately 
obvious causal role for a trait or disorder42. Additionally, 
there is an ongoing debate on the ethical implications of 
disclosing incidental genomic findings to patients, i.e. DNA 
variants known to predispose to diseases other than the one 
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being investigated at that particular moment43-45. Equally 
important is the concern of how to best protect the privacy 
of an individual’s genomic data – as with any genetic 
testing, confidentiality and data protection are paramount.
Thousands of variants identified in individual 
genomes may indeed not have a detectable biological 
effect. In order to differentiate truly silent variants from 
those with a functional impact, huge efforts are being put 
into sequencing entire genomes of large populations, trying 
to ascertain both genetic variability and the relationship of 
variants, isolated or in combination, with phenotypic traits 
and diseases46. To accompany the identification of all these 
DNA variants, new technologies will certainly need to be 
developed and fine-tuned to allow equally massive means 
of interpretation of functional effect, which will hopefully 
permit translation of this knowledge to the clinical setting 
and a true benefit to our patients.
CONCLUSION
Molecular diagnosis in endocrinology is fast moving 
from rare disorders confined to academic institutions to 
common endocrinopathies present in the everyday clinic. 
At the moment, genetic testing is warranted when the 
benefits of a molecular definition are clear and outweighs 
potential risks, which always should be assessed and 
discussed with the patients. Examples of such situations 
where benefits are clear include the management of 
multiple endocrine neoplasia syndromes and some isolated 
endocrine cancers. Several types of genetic tests can be 
done, and their choice depends on the disorder under study 
and technical availability. Soon, increased accessibility to 
massive parallel sequencing technologies and improved 
interpretation of the functional impact of DNA variants 
identified this way will bring molecular information to 
the clinical setting with full force, helping us offer a more 
personalised care to our patients.
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